Castle Biosciences CEO Derek J. Maetzold reports $462,567.36 share disposal

CSTL•2026-10-21

Castle Biosciences President and CEO Derek J. Maetzold sold 14,496 common shares on Oct. 19, 2026, at $31.91 per share, for a total of $462,567.36.

1. Share sale details

Maetzold sold 8,580 directly held shares, reducing his direct holdings to 12,484 shares. Trusts accounted for the remaining 5,916 shares sold, according to a Form 4 dated Oct. 21, 2026.

Sources

Castle Biosciences CEO Derek J. Maetzold reports $462,567.36 share disposal

Sec

Castle Biosciences CEO Derek J. Maetzold reports $462,567.36 share disposal

1. Share sale details

Related News

Cathay General Bancorp Q3 net income rises on higher interest income from loans

TJX files initial beneficial ownership statement for SEVP-Group President John Ricciuti

Integer Holdings shareholders approve acquisition by KKR

Sources

Castle Biosciences CEO Derek J. Maetzold reports $462,567.36 share disposal

Bank of America names Jim Fitterling and Bill Thomas to board of directors

Civista Bancshares declares quarterly dividend of 18 cents per share